BRPI0408061A - tratamento médico utilizando um agonista de receptores seletivos de ep 2 - Google Patents

tratamento médico utilizando um agonista de receptores seletivos de ep 2

Info

Publication number
BRPI0408061A
BRPI0408061A BRPI0408061-0A BRPI0408061A BRPI0408061A BR PI0408061 A BRPI0408061 A BR PI0408061A BR PI0408061 A BRPI0408061 A BR PI0408061A BR PI0408061 A BRPI0408061 A BR PI0408061A
Authority
BR
Brazil
Prior art keywords
facilitating
receptor agonist
treating
repair
medical treatment
Prior art date
Application number
BRPI0408061-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0408061A publication Critical patent/BRPI0408061A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0408061-0A 2003-03-04 2004-02-23 tratamento médico utilizando um agonista de receptores seletivos de ep 2 BRPI0408061A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04
PCT/IB2004/000553 WO2004078169A1 (fr) 2003-03-04 2004-02-23 Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical

Publications (1)

Publication Number Publication Date
BRPI0408061A true BRPI0408061A (pt) 2006-02-14

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408061-0A BRPI0408061A (pt) 2003-03-04 2004-02-23 tratamento médico utilizando um agonista de receptores seletivos de ep 2

Country Status (14)

Country Link
EP (1) EP1601351A1 (fr)
JP (1) JP2006519250A (fr)
KR (1) KR20050105511A (fr)
CN (1) CN1859903A (fr)
AU (1) AU2004216898A1 (fr)
BR (1) BRPI0408061A (fr)
CA (1) CA2518193A1 (fr)
CL (1) CL2004000412A1 (fr)
MX (1) MXPA05009398A (fr)
NZ (1) NZ541828A (fr)
PL (1) PL378748A1 (fr)
TW (1) TW200424176A (fr)
WO (1) WO2004078169A1 (fr)
ZA (1) ZA200506532B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP2422814A1 (fr) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remède pour maladies associées aux cartilages
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2605214C (fr) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Nouveaux derives de benzylamine en tant qu'inhibiteurs de cetp
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
EP3824885A1 (fr) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Procédé pour améliorer la régénération tissulaire
EP2195656A4 (fr) * 2007-08-21 2011-10-19 Senomyx Inc Recepteurs humains t2r sensibles aux composes amers qui provoquent le gout amer, et utilisation de ceux-ci
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
WO2010096264A2 (fr) 2009-02-03 2010-08-26 Children's Medical Center Corporation Procédés permettant d'améliorer la greffe de cellules souches hématopoïétiques et les cellules progénitrices hématopoïétiques
WO2010091052A2 (fr) 2009-02-03 2010-08-12 Children's Medical Center Corporation Procédés de renforcement de greffe de cellule souche hématopoïétique/progénitrice
PT2415763E (pt) * 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
WO2010116270A1 (fr) 2009-04-10 2010-10-14 Pfizer Inc. Agonistes de ep2/4
EP2476668B1 (fr) * 2009-09-11 2013-11-06 Ube Industries, Ltd. Composés aniline
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
CN102666490A (zh) * 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
EP2744803A2 (fr) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Composés amines hétérocycliques substitués comme inhibiteurs de la protéine de transfert d'ester cholesterylique (cetp)
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
EP2785350B1 (fr) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Méthodes améliorées permettant de traiter l'ischémie
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
EP2804605A4 (fr) * 2012-01-20 2015-07-08 Acucela Inc Composés hétérocycliques substitués pour le traitement d'une maladie
US20140142092A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
WO2014150602A1 (fr) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Essai d'activité biologique de cellules pour un potentiel thérapeutique
HK1219103A1 (en) 2013-03-28 2017-03-24 Ube Industries, Ltd. Substituted biaryl compound
DK3143026T3 (da) 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
CN115636761B (zh) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 一种油溶性表面活性剂、驱油剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (fr) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Sulfonamides carbocycliques
ES2303341T3 (es) * 1996-12-20 2008-08-01 Pfizer Inc. Prevencion y tratamiento de trastorno del esqueleto con agonistas de la prostaglandina e2 selectivos del subtipo de receptor ep2.
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
JP2006519250A (ja) 2006-08-24
NZ541828A (en) 2008-06-30
CN1859903A (zh) 2006-11-08
CL2004000412A1 (es) 2005-02-04
KR20050105511A (ko) 2005-11-04
TW200424176A (en) 2004-11-16
WO2004078169A1 (fr) 2004-09-16
CA2518193A1 (fr) 2004-09-16
PL378748A1 (pl) 2006-05-15
EP1601351A1 (fr) 2005-12-07
AU2004216898A1 (en) 2004-09-16
ZA200506532B (en) 2007-03-28
MXPA05009398A (es) 2005-12-05
WO2004078169A8 (fr) 2005-04-21

Similar Documents

Publication Publication Date Title
BRPI0408061A (pt) tratamento médico utilizando um agonista de receptores seletivos de ep 2
PT881908E (pt) Utilizacao dos factores de crescimento de fibroblasto para estimular o crescimento osseo
Masri et al. Seven specialized exposures for revision hip and knee replacement
EP0950417A3 (fr) Traitement d' anomalies du squelette
Atesalp et al. Treatment of tibial bone defects with the Ilizarov circular external fixator in high-velocity gunshot wounds
WO2001080894A3 (fr) Utilisation d'antagonistes ou d'agonistes du recepteur retinoide dans le traitement de pathologies des cartilages et os
Bundgaard et al. Tibial bone loss and soft-tissue defect treated simultaneously with Ilizarov-technique--a case report
Walker Discussion: Open reduction of condylar fractures of the mandible in conjunction with repair of discal injury: A preliminary report
US20230218324A1 (en) Bone reductionand plate fixation forceps
Kaushal et al. Comminuted intra-articular fractures of the distal humerus
RU2048795C1 (ru) Способ лечения деформирующего артроза коленного сустава
RU2285478C2 (ru) Способ лечения застарелого вывиха головки локтевой кости
De Carolis et al. A lifelong story: Case report of a humeral shaft nonunion successfully treated after 30 years
Jobe En bloc nasal shift rhinoplasty—an approach to the small crooked nose
RU2000103308A (ru) Способ остеосинтеза внутрисуставных компрессионных переломов мыщелков большеберцовой кости под контролем артроскопии
RU2264185C1 (ru) Способ лечения привычного вывиха плеча
Laverick et al. Re: Devlin et al. Open reduction and internal fixation of fractured mandibular condyles by a retromandibular approach: surgical morbidity and informed consent. Br J Oral Maxillofac Surg 2002; 40: 23-25
ATE270863T1 (de) Gelenkimplantat und zugehörige hilfsinstrumente
RU2208409C2 (ru) Способ открытого вправления локтевой кости при ее застарелом вывихе
SU1367957A1 (ru) Способ лечени врожденного расщеплени кисти
Sarmol et al. Outcome and Evaluation of Olecranonplasty using Delayed Absorbable Suture Materials of Olecranon Fracture: A Novel Repair Method
RU2392895C1 (ru) Способ хирургического лечения привычного вывиха плеча
SU1503774A1 (ru) Способ лечени деформирующего артроза коленного сустава
RU2025097C1 (ru) Способ лечения сгибательной контрактуры коленного сустава
RU2000104552A (ru) Способ лечения передне-наружной ротационной нестабильности коленного сустава

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.